Hypoglycaemia due to inherited metabolic disease — branching viva

Opening framework

My framework has three layers. First, the recognition — a child with neuroglycopenia after a fast or illness is a metabolic emergency until proven otherwise, and the critical sample drawn while the child is hypoglycaemic is the single most important diagnostic act. Second, the physiology — glucose homeostasis is a balance between supply and utilisation, and ketones are the brain's alternate fuel, so a child who cannot make ketones is doubly exposed. Third, the classification — three physiological failures (insulin-driven, glucose-production, fuel-oxidation) are localised by the insulin, beta-hydroxybutyrate, free-fatty-acid and lactate pattern, and each carries its own therapy. [1] [9]

The emergency principle and the critical sample

The cardinal principle is to correct glucose immediately while preserving the diagnostic window: draw the critical sample first if it is safe, then treat, and if the child is seizing, treat first and sample in the recovery window. The reason the sample is mandatory is that the hormone and metabolite profile — insulin, beta-hydroxybutyrate, free fatty acids, lactate, ammonia, growth hormone and cortisol — normalises the moment glucose is corrected, so a missed sample can delay the diagnosis for years and allow a fatal recurrence. The bolus is 0.3 grams per kilogram (2 mL/kg of 10 percent dextrose) and the infusion is 6 to 9 mg/kg/min titrated to a glucose above 3.5 mmol/L. [1]

Localising the cause with the critical-sample pattern

The pattern is read relationally, not in isolation. A measurable insulin at a low glucose is itself pathological, and when it accompanies suppressed beta-hydroxybutyrate and suppressed free fatty acids it indicates congenital hyperinsulinism, because insulin is an anabolic hormone that drives uptake and switches off both glycogenolysis and lipolysis. A low insulin with high free fatty acids but inappropriately low ketones indicates a fatty-acid oxidation defect: the body has mobilised fat but cannot oxidise it into ketones. Hypoglycaemia with a high lactate, hyperuricaemia and hepatomegaly indicates glycogen storage disease type I, where glucose-6-phosphate is shunted to lactate. A ketotic profile with an appropriate counter-regulatory response points toward idiopathic ketotic hypoglycaemia once the inherited and endocrine causes are excluded. [9] [6]

The glucagon response during hypoglycaemia is both diagnostic and therapeutic. A glycaemic rise of more than 1.5 to 2.0 mmol/L after intramuscular or intravenous glucagon indicates that glycogen is present and mobilisable and that insulin is high, confirming congenital hyperinsulinism; no response suggests a glycogen storage or gluconeogenesis disorder. The fasting-tolerance history is the complementary bedside tool: a child who decompensates within four to six hours has a glycogenolysis or gluconeogenesis defect, while a child who tolerates a fast to twelve hours then collapses has a fatty-acid oxidation defect. [1]

Branch: the neonate with high-glucose-requirement hypoglycaemia

For the neonate requiring more than 10 to 12 mg/kg/min with a measurable insulin, suppressed ketones and a positive glucagon response, the diagnosis is congenital hyperinsulinism. The medical ladder is diazoxide first — a KATP-channel opener — but the recessive KATP-channel forms (ABCC8, KCNJ11) are typically diazoxide-unresponsive, in which case sirolimus (an mTOR inhibitor) and octreotide or lanreotide are used. The pivotal distinction is diffuse versus focal: a focal lesion, from a paternally inherited mutation with somatic loss of the maternal allele in a single adenomatous area, is curable by limited pancreatectomy, while diffuse disease requires medical suppression or near-total pancreatectomy, which trades hypoglycaemia for diabetes and exocrine insufficiency. The distinction is made by the genetic pattern and 18-fluorodopa positron-emission tomography, and the Kapoor and Snider cohorts established that genotype predicts histology, diazoxide response, and surgical strategy. [2]

Closing: disease-specific long-term care and the trap to avoid

Disease-specific long-term care follows the physiological failure. For congenital hyperinsulinism it is diazoxide, sirolimus, and surgery for the unresponsive case. For the fatty-acid oxidation defects it is fasting avoidance, frequent feeds, a written sick-day plan, and carnitine where indicated — with medium-chain triglyceride oil in the long-chain disorders to bypass the block. For glycogen storage disease type I it is uncooked cornstarch and frequent feeds to sustain a continuous glucose supply, with fructose and galactose restriction. The trap is to send a hypoglycaemic child home without a critical sample and a provisional diagnosis, because the inherited causes are intermittent and a single normal glucose when well does not exclude them — and a missed fatty-acid oxidation defect can present later as sudden death. The closing point is that the speed and completeness of the first episode's management is the single most powerful modifier of the lifelong neurodevelopmental outcome. [6] [1]